A Contract Research Organization (CRO) delivers protocol design, site management, monitoring, biostatistics, regulatory submissions, safety reporting, and data management on behalf of device, IVD, biotech, and pharma sponsors. MedTech-focused CROs differ from drug CROs in their handling of device-specific endpoints, IRB/EC strategy for IDE/CIP studies, and reimbursement-grade evidence design.

Why it matters

Sponsors choose CROs based on therapeutic-area expertise, geographic site footprint, and budget - and increasingly on familiarity with EU MDR/IVDR clinical evidence expectations.

Common pitfalls

•Failing to establish clear lines of responsibility and communication between the sponsor and the CRO can lead to regulatory non-compliance.
•Assuming that a CRO is solely responsible for regulatory compliance without adequate sponsor oversight is a common pitfall.
•Not performing due diligence on a CRO's quality management system or therapeutic area expertise can result in compromised study data or delayed submissions.
•Lack of a comprehensive written agreement detailing all delegated tasks and responsibilities can create disputes and regulatory scrutiny.
•Overlooking the need for ongoing sponsor monitoring of CRO activities, even for seemingly minor tasks, can lead to critical errors being missed.

Sources

ACRO · ACRO
AdvaMed · AdvaMed
MedTech Europe · MedTech Europe
FDA definition of a CRO in drug investigations (21 CFR 312.3) · Electronic Code of Federal Regulations / FDA regulation

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.